发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Australian Prescriber peer reviewers, 2023 to 2025. 澳大利亚处方同行评审，2023年至2025年。
IF 4.2
Australian Prescriber Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.051
{"title":"<i>Australian Prescriber</i> peer reviewers, 2023 to 2025.","authors":"","doi":"10.18773/austprescr.2025.051","DOIUrl":"https://doi.org/10.18773/austprescr.2025.051","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"216"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fifty years of Australian Prescriber - continuing a proud tradition of trusted, independent information. 五十年的澳大利亚处方-继续一个值得骄傲的传统，值得信赖的，独立的信息。
IF 4.2
Australian Prescriber Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.056
Michael Kidd
{"title":"Fifty years of <i>Australian Prescriber</i> <b>-</b> continuing a proud tradition of trusted, independent information.","authors":"Michael Kidd","doi":"10.18773/austprescr.2025.056","DOIUrl":"10.18773/austprescr.2025.056","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"192-193"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calcifediol high-strength formulation for vitamin D deficiency. 钙化二醇高强度配方，用于维生素D缺乏。
IF 4.2
Australian Prescriber Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.050
{"title":"Calcifediol high-strength formulation for vitamin D deficiency.","authors":"","doi":"10.18773/austprescr.2025.050","DOIUrl":"10.18773/austprescr.2025.050","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"212-213"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypertension - a major modifiable and undertreated risk factor. 高血压-一个主要的可改变和治疗不足的危险因素。
IF 4.2
Australian Prescriber Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.049
Charlotte Hespe, Nigel Stocks, Mark Nelson
{"title":"Hypertension - a major modifiable and undertreated risk factor.","authors":"Charlotte Hespe, Nigel Stocks, Mark Nelson","doi":"10.18773/austprescr.2025.049","DOIUrl":"10.18773/austprescr.2025.049","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"194-196"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Injectable drugs for weight management. 用于控制体重的注射药物。
IF 4.2
Australian Prescriber Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.052
Natasha Yates, Terri-Lynne South
{"title":"Injectable drugs for weight management.","authors":"Natasha Yates, Terri-Lynne South","doi":"10.18773/austprescr.2025.052","DOIUrl":"10.18773/austprescr.2025.052","url":null,"abstract":"<p><p>Obesity management is complex; medications must be used in conjunction with behavioural changes and monitoring by health professionals. Injectable drugs for weight management include glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. liraglutide, semaglutide) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (e.g. tirzepatide). These drugs contribute to weight loss by mimicking the incretin hormones GLP-1 and GIP to reduce appetite, change food enjoyment, slow stomach emptying and stimulate insulin release. Regaining weight is common when these drugs are stopped, so they usually need to be continued long term. Relatively minor gastrointestinal issues are common. There is also a small but real risk of more serious adverse effects, including gallstones and pancreatitis. It is important to monitor mental health, as these drugs can change a patient's relationship with food, and they may be misused by those without obesity.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"197-202"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testing for human immunodeficiency virus. 人类免疫缺陷病毒测试。
IF 4.2
Australian Prescriber Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.048
Louise Owen, Ian Woolley
{"title":"Testing for human immunodeficiency virus.","authors":"Louise Owen, Ian Woolley","doi":"10.18773/austprescr.2025.048","DOIUrl":"10.18773/austprescr.2025.048","url":null,"abstract":"<p><p>Testing for human immunodeficiency virus (HIV) is recommended for individuals with behavioural or epidemiological risk factors, and those who present with clinical indicator conditions. Routine testing is recommended in pregnancy and as part of symptomatic and asymptomatic sexually transmissible infection check-ups. In Australia, laboratories primarily use combined HIV antibody and antigen tests for diagnostic testing. A reactive test is followed by a laboratory confirmatory test. Clinicians should consider whether the person is within the testing window period when interpreting results. On receipt of a confirmed HIV-positive result, healthcare providers must discuss the result and contact tracing with the patient, and ideally refer them to specialised services, including an HIV care provider.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"203-207"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological management of attention deficit hyperactivity disorder in children and adolescents. 儿童和青少年注意缺陷多动障碍的药物治疗。
IF 4.2
Australian Prescriber Pub Date : 2025-10-01 DOI: 10.18773/austprescr.2025.043
Daryl Efron, Nadia Coscini
{"title":"Pharmacological management of attention deficit hyperactivity disorder in children and adolescents.","authors":"Daryl Efron, Nadia Coscini","doi":"10.18773/austprescr.2025.043","DOIUrl":"10.18773/austprescr.2025.043","url":null,"abstract":"<p><p>Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterised by developmentally inappropriate levels of hyperactivity, impulsivity and/or inattention, with substantial impact on functioning. Stimulants (methylphenidate, dexamfetamine, lisdexamfetamine) are the main pharmacological treatment for children and adolescents with ADHD and are highly effective at reducing core ADHD symptoms. Non-stimulants such as atomoxetine, clonidine and guanfacine can also be useful in some patients.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 5","pages":"156-160"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12566444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145403110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral anticoagulation for adults with atrial fibrillation or venous thromboembolism. 成人房颤或静脉血栓栓塞的口服抗凝治疗。
IF 4.2
Australian Prescriber Pub Date : 2025-10-01 DOI: 10.18773/austprescr.2025.047
Paul Kl Chin, Matthew P Doogue
{"title":"Oral anticoagulation for adults with atrial fibrillation or venous thromboembolism.","authors":"Paul Kl Chin, Matthew P Doogue","doi":"10.18773/austprescr.2025.047","DOIUrl":"10.18773/austprescr.2025.047","url":null,"abstract":"<p><p>Most patients with non-valvular atrial fibrillation (AF) or acute venous thromboembolism (VTE) can be treated with a direct-acting oral anticoagulant (DOAC); currently available DOACs are apixaban, rivaroxaban and dabigatran. Warfarin is the first-line oral anticoagulant for valvular AF in patients with mechanical heart valves or rheumatic mitral stenosis. Apixaban and rivaroxaban are first-line oral anticoagulants for cancer-associated VTE, and for AF or VTE in patients with body mass index over 35 kg/m<sup>2</sup> or actual body weight over 120 kg. All DOACs require dose adjustment in people with moderate kidney impairment. Routine laboratory measurement of drug concentrations or relevant coagulation function assays is not required for safe and effective use of DOACs; however, there are situations when it may be beneficial, including emergency scenarios requiring normal haemostasis and where excessive or inadequate anticoagulation is suspected.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 5","pages":"161-166"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12566413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145403120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aminoglycoside dosing and kidney function: which equation to use? 氨基糖苷剂量与肾功能：使用哪个方程式？
IF 4.2
Australian Prescriber Pub Date : 2025-10-01 DOI: 10.18773/austprescr.2025.044
{"title":"Aminoglycoside dosing and kidney function: which equation to use?","authors":"","doi":"10.18773/austprescr.2025.044","DOIUrl":"10.18773/austprescr.2025.044","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 5","pages":"181"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12566437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145402952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Edaravone for amyotrophic lateral sclerosis. 依达拉奉治疗肌萎缩性侧索硬化。
IF 4.2
Australian Prescriber Pub Date : 2025-10-01 DOI: 10.18773/austprescr.2025.041
{"title":"Edaravone for amyotrophic lateral sclerosis.","authors":"","doi":"10.18773/austprescr.2025.041","DOIUrl":"10.18773/austprescr.2025.041","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 5","pages":"182-183"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12566403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145402955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书